AHA GUIDELINES Bundle (free trial)

2017 Update Incorporated - Valvular Heart Disease

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/362033

Contents of this Issue

Navigation

Page 20 of 63

21 Valve Hemodynamics a Hemodynamic Consequences Symptoms • Normal transmitral flow velocity • None None • Increased transmitral flow velocities • MVA >1.5 cm 2 • Diastolic pressure half-time <150 ms • Mild-to-moderate left atrium (LA) enlargement • Normal pulmonary pressure at rest None • MVA ≤1.5 cm 2 (MVA ≤1.0 cm 2 with severe MS) • Diastolic pressure half-time ≥150 ms (Diastolic pressure half-time ≥220 ms with severe MS) • Severe LA enlargement • Elevated PASP >30 mm Hg None • MVA ≤1.5 cm 2 (MVA ≤1.0 cm 2 with very severe MS) • Diastolic pressure half-time ≥150 ms (Diastolic pressure half-time ≥220 ms with very severe MS) • Severe LA enlargement • Elevated PASP >30 mm Hg • Decreased exercise tolerance • Exertional dyspnea a e transmitral ΔPmean should be obtained to further determine the hemodynamic effect of the MS and is usually >5–10 mm Hg in severe MS. However, due to the variability of the ΔPmean with heart rate and forward flow, it has not been included in the criteria for severity.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - 2017 Update Incorporated - Valvular Heart Disease